Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.
Zeina Beidas, Anya Ragnhildstveit, Adam Blackman, Thomas Anderson, Emily Fewster, Omer A. Syed, Valentyne Sobolenko, Ismail Kaan Kanca, Tatiana Son, Norman Farb, Rotem Petranker
BJPsych Open May 13, 2026 DOI: 10.1192/bjo.2026.12000 via PubMed Central
Summary
AI-generated from the abstractThis is a correction notice for a previously published study protocol. The original protocol describes a phase II double-blind placebo-controlled randomised partial crossover trial investigating microdosing psilocybin for major depressive disorder. No new findings or data are presented.
Study at a glance
| Characteristics | Corrigendum Randomized Placebo-controlled Double-blind Peer reviewed |
|---|---|
| Population | Major depressive disorder |
| Key finding | This is a corrigendum to a study protocol for microdosing psilocybin for MDD; no results. |
Abstract
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.